Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

The Blood-brain Barrier00:49

The Blood-brain Barrier

52.2K
Overview
52.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity.

Nature medicine·2024
Same author

Cellular architecture shapes the naïve T cell response.

Science (New York, N.Y.)·2024
Same author

Targeting the Siglec-sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma.

Science translational medicine·2023
Same author

Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022

相关实验视频

Updated: Jan 11, 2026

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

2.2K

质母细胞瘤中的神经脆弱性:通过神经活性药物重新定位重新思考治疗方法

Paola Onate Colobon1, Sohyon Lee1,2,3,4

  • 1Department of Biological Sciences, Korea Advanced Institute of Science & Technology (KAIST), Daejeon, Korea.

Brain tumor research and treatment
|November 11, 2025
PubMed
概括

由于血脑屏障和瘤异质性,质母细胞瘤的治疗面临着挑战. 重用神经活性药物 (NAD) 通过向瘤的神经特性,提供了一个有前途的新策略.

关键词:
癌症神经科学 癌症神经科学药物重新定位是药物重新定位.质母细胞瘤 (glioblastoma) 是一个神经活性药物的神经活性药物

更多相关视频

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.0K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.1K

相关实验视频

Last Updated: Jan 11, 2026

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

2.2K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.0K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.1K

科学领域:

  • 神经瘤学神经瘤学
  • 癌症神经科学 癌症神经科学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 质母细胞瘤是一种侵袭性脑癌,治疗疗效和生存率有限.
  • 关键的挑战包括血脑屏障,瘤异质性和不充分的临床前模型.
  • 癌症神经科学揭示了质母细胞瘤对神经发育和神经生理过程的依赖.

研究的目的:

  • 审查用于药物发现的质母细胞瘤临床前模型.
  • 探索瘤神经特征所带来的治疗机会.
  • 突出重定位神经活性药物 (NADs) 在质母细胞瘤治疗中的潜力.

主要方法:

  • 对现有的质母细胞瘤临床前模型的文献综述.
  • 分析癌症神经科学中新出现的证据.
  • 对神经活性药物 (NAD) 重定位研究的审查.

主要成果:

  • 临床前模型对于质母细胞瘤药物发现至关重要,但往往不足.
  • 质母细胞瘤表现出类似神经系统的特性,可以在治疗上准.
  • 神经活性药物 (NAD) 可以穿越血脑屏障,并可能影响这些神经特性.

结论:

  • 利用质母细胞瘤的神经特性提供了一个新的治疗途径.
  • 重定位已批准的神经活性药物 (NAD) 是一个有前途的模式转变为质母细胞瘤治疗.
  • 需要进一步的研究来阐明质母细胞瘤中NADs的机制.